Last reviewed · How we verify
Placebo to losartan potassium
Losartan potassium is an angiotensin II receptor antagonist that blocks the action of angiotensin II at its receptor in the blood vessels, causing them to relax and dilate, which lowers blood pressure and reduces the workload on the heart.
Losartan potassium is an angiotensin II receptor antagonist that blocks the action of angiotensin II at its receptor in the blood vessels, causing them to relax and dilate, which lowers blood pressure and reduces the workload on the heart. Used for Hypertension, Diabetic nephropathy.
At a glance
| Generic name | Placebo to losartan potassium |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Angiotensin II receptor antagonist |
| Target | AT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This results in decreased peripheral resistance and a subsequent decrease in blood pressure. Losartan also has a mild diuretic effect, which helps to reduce fluid volume and further lower blood pressure.
Approved indications
- Hypertension
- Diabetic nephropathy
Common side effects
- Dizziness
- Headache
- Fatigue
- Cough
- Nausea
Key clinical trials
- Losartan for Corneal Fibrosis (NA)
- Losartan to Improve Outcomes After Multi-ligament Knee Injury (PHASE2)
- Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction (PHASE4)
- Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19 (PHASE3)
- Losartan and Social Processing (EARLY_PHASE1)
- Secondhand Tobacco Smoke and Cardiovascular Disease (PHASE4)
- Losartan for Improved Vascular Endothelial Function After Preeclampsia (EARLY_PHASE1)
- Losartan and Emotional Processing in Young People (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to losartan potassium CI brief — competitive landscape report
- Placebo to losartan potassium updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI